Urogenital schistosomiasis in children and adolescents

Poliakov, V.E.; Klaĭshevich, G.I.; Poliakov, N.V.

Urologiia 5(2): 49-54

2000


ISSN/ISBN: 1728-2985
PMID: 11186738
Document Number: 522873
The study was made of dalphas-retard safety and effectiveness in 940 patients with benign prostatic hyperplasia and relevant urination problems. The drug was given in a dose 5-10 mg/day for 12 weeks. The results were assessed in 881 patients who had completed the treatment course. 18 patients (1.9%) discontinued the treatment because of side effects. 38 patients (4%) had side effects once or more times.

Document emailed within 1 workday
Secure & encrypted payments